Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Furst

Showing results (81-90 of 251) with videos related to

Pageof 26
Sort By:
Rheumatology (Oxford, England)|September 17, 2008
Trial design: how must we move ahead?J R Seibold, A Tyndall, D E Furst
Journal of Pharmaceutical Sciences|November 1, 1984
Metabolism of salsalate in normal subjectsS H Dromgoole, D E Furst, H E Paulus
Journal of Chromatography|February 24, 1989
Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatographyB Nuernberg, M Kohlbrenner, R Faulkner, et al.
Arthritis and Rheumatism|November 11, 1999
High-dose immunosuppressive therapy for rheumatoid arthritis: some answers, more questionsP A McSweeney, D E Furst, S G West
Clinical Pharmacokinetics|March 1, 1986
Clinical pharmacokinetics of oral and injectable gold compoundsK L Blocka, H E Paulus, D E Furst
The Journal of Rheumatology|February 1, 1987
Salicylate toxicity in elderly patients with rheumatoid arthritisR R Grigor, P W Spitz, D E Furst
The Journal of Rheumatology|May 1, 1992
Why everything (or nothing) seems to work in the treatment of sclerodermaJ R Seibold, D E Furst, P J Clements
Clinical Pharmacology and Therapeutics|September 1, 1979
Salicylate clearance, the resultant of protein binding and metabolismD E Furst, T N Tozer, K L Melmon
The Journal of Rheumatology|September 1, 1996
Results of "satisfaction with disease control" surveyD E Furst, K R Wilske, D E Stage
The Journal of Rheumatology|August 1, 1993
Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexateT W Rooney, D E Furst, R Koehnke, et al.
Pageof 26

Showing results (81-90 of 251) with videos related to

Sort By:
Pageof 26
Rheumatology (Oxford, England)|September 17, 2008
Trial design: how must we move ahead?J R Seibold, A Tyndall, D E Furst
Journal of Pharmaceutical Sciences|November 1, 1984
Metabolism of salsalate in normal subjectsS H Dromgoole, D E Furst, H E Paulus
Journal of Chromatography|February 24, 1989
Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatographyB Nuernberg, M Kohlbrenner, R Faulkner, et al.
Arthritis and Rheumatism|November 11, 1999
High-dose immunosuppressive therapy for rheumatoid arthritis: some answers, more questionsP A McSweeney, D E Furst, S G West
Clinical Pharmacokinetics|March 1, 1986
Clinical pharmacokinetics of oral and injectable gold compoundsK L Blocka, H E Paulus, D E Furst
The Journal of Rheumatology|February 1, 1987
Salicylate toxicity in elderly patients with rheumatoid arthritisR R Grigor, P W Spitz, D E Furst
The Journal of Rheumatology|May 1, 1992
Why everything (or nothing) seems to work in the treatment of sclerodermaJ R Seibold, D E Furst, P J Clements
Clinical Pharmacology and Therapeutics|September 1, 1979
Salicylate clearance, the resultant of protein binding and metabolismD E Furst, T N Tozer, K L Melmon
The Journal of Rheumatology|September 1, 1996
Results of "satisfaction with disease control" surveyD E Furst, K R Wilske, D E Stage
The Journal of Rheumatology|August 1, 1993
Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexateT W Rooney, D E Furst, R Koehnke, et al.
Pageof 26